Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4539MR)

This product GTTS-WQ4539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4539MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2866MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ3707MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ13446MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ14366MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13494MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4982MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ2497MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ11277MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW